Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression

A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We present a mathematical model of the penultimate stage in such a progression. We assume the tumour has reached the limit of its present growth potential due to cell competition that either results in total birth rate reduction or death rate increase. The tumour can then progress to the final stage by either seeding a metastasis or acquiring a driver mutation. We influence the ensuing evolutionary dynamics by cytotoxic (increasing death rate) or cytostatic (decreasing birth rate) therapy while keeping the effect of the therapy on net growth reduction constant. Comparing the treatments head to head we derive conditions for choosing optimal therapy. We quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates, and the details of cell competition. We show that detailed understanding of the cell population dynamics could be exploited in choosing the right mode of treatment with substantial therapy gains.

[1]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.

[2]  Wei Liu,et al.  Bottom-up precise synthesis of stable platinum dimers on graphene , 2017, Nature Communications.

[3]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[4]  M. Stratton,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[5]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[6]  Minsu Kim,et al.  Antibiotic-induced population fluctuations and stochastic clearance of bacteria , 2018, eLife.

[7]  T. Fojo,et al.  Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? , 2007, Clinical Cancer Research.

[8]  M. Clynes,et al.  Examining the relationship between cancer invasion/metastasis and drug resistance. , 2002, Current cancer drug targets.

[9]  Valentina Rossetti,et al.  Emergent multicellular life cycles in filamentous bacteria owing to density-dependent population dynamics , 2011, Journal of The Royal Society Interface.

[10]  Marc J. Williams,et al.  Identification of neutral tumor evolution across cancer types , 2016, Nature Genetics.

[11]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[12]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[13]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[14]  B. Perthame,et al.  Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[15]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[16]  Lewis H. Mervin,et al.  Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection. , 2016, ACS chemical biology.

[17]  Martin A. Nowak,et al.  A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity , 2015, Nature.

[18]  Sang Gyun Kim,et al.  Rapamycin: one drug, many effects. , 2014, Cell metabolism.

[19]  R. Busa-Fekete,et al.  Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent , 2014, Antimicrobial Agents and Chemotherapy.

[20]  Robert J Woods,et al.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient , 2017, PLoS biology.

[21]  Heyrim Cho,et al.  Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy , 2017, Bulletin of Mathematical Biology.

[22]  Ahmad S. Khalil,et al.  Antibiotic efficacy is linked to bacterial cellular respiration. , 2015, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Ville Mustonen,et al.  The value of monitoring to control evolving populations , 2014, Proceedings of the National Academy of Sciences.

[24]  C. Thompson,et al.  The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment , 2007, Clinical Cancer Research.

[25]  P. Armitage,et al.  The age distribution of cancer and a multi-stage theory of carcinogenesis , 1954, British Journal of Cancer.

[26]  M. Tubiana.  Tumor cell proliferation kinetics and tumor growth rate. , 1989, Acta oncologica.

[27]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[28]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[29]  Andrea Sottoriva,et al.  Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.

[30]  Robert Gatenby,et al.  Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer , 2015, Proceedings of the National Academy of Sciences.

[31]  Charles Swanton,et al.  Metastasis as an evolutionary process , 2016, Science.

[32]  Joel s. Brown,et al.  Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.

[33]  William H. Sanders,et al.  Dynamic partitioning for hybrid simulation of the bistable HIV-1 transactivation network , 2006, Bioinform..

[34]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[35]  Benjamin J. Raphael,et al.  The evolutionary history of 2,658 cancers , 2017, Nature.

[36]  R. Matkowski,et al.  Circulating Tumor , 2014 .

[37]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[38]  B. Krishnamachary,et al.  Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents , 2016, Front. Oncol..

[39]  Martin A. Nowak,et al.  Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution , 2016, PLoS Comput. Biol..

[40]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[41]  Fredrik Ponten,et al.  Antibody-based proteomics: fast-tracking molecular diagnostics in oncology , 2010, Nature Reviews Cancer.

[42]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[43]  M. Erlacher,et al.  How cell death shapes cancer , 2015, Cell Death and Disease.

[44]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[45]  Naveen Garg,et al.  Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. , 2017, JCI insight.

[46]  Melissa L. Johnson,et al.  Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.

[47]  O. Ovaskainen,et al.  Stochastic models of population extinction. , 2010, Trends in ecology & evolution.

[48]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[50]  Troy Day,et al.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.

[51]  Joel s. Brown,et al.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.